ArticleThe American journal of pathology2007
RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth.
Article in The American journal of pathology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 62 citations in OpenAlex.
- Advanced glycation end products and risk of mortality in patients with cirrhosis: a prospective cohort study.Scientific reports · 2025Article
- HMGB1/RAGE axis in tumor development: unraveling its significance.Frontiers in oncology · 2024Review
- RAGE Up-Regulation Differently Affects Cell Proliferation and Migration in Pancreatic Cancer Cells.International journal of molecular sciences · 2020Article
- S100A4 is secreted by airway smooth muscle tissues and activates inflammatory signaling pathways via receptors for advanced glycation end products.American journal of physiology. Lung cellular and molecular physiology · 2020Article
- Role and Mechanisms of RAGE-Ligand Complexes and RAGE-Inhibitors in Cancer Progression.International journal of molecular sciences · 2020Review
- Receptor for Advanced Glycation End Products Acts as a Fuel to Colorectal Cancer Development.Frontiers in oncology · 2020Review
- Biological functions and theranostic potential of HMGB family members in human cancers.Therapeutic advances in medical oncology · 2020Review
- Spatial and temporal changes in myogenic protein expression by the microenvironment after freeze injury.Journal of anatomy · 2019Article
- RAGE in the pathophysiology of skeletal muscle.Journal of cachexia, sarcopenia and muscle · 2018Review
- Use of a novel camelid-inspired human antibody demonstrates the importance of MMP-14 to cancer stem cell function in the metastatic process.Oncotarget · 2018Article
- Paradoxical Role of High Mobility Group Box 1 in Glioma: A Suppressor or a Promoter?Oncology reviews · 2017Review
- Stem cell activation in skeletal muscle regeneration.Cellular and molecular life sciences : CMLS · 2015Review
- HMGB1 in health and disease.Molecular aspects of medicine · 2014Review
- Knockdown of HMGB1 improves apoptosis and suppresses proliferation and invasion of glioma cells.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2014Article
- RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer.Cell death & disease · 2014Article
- Review
- HuR and miR-1192 regulate myogenesis by modulating the translation of HMGB1 mRNA.Nature communications · 2013Article
- Rhabdomyosarcomas: an overview on the experimental animal models.Journal of cellular and molecular medicine · 2012Review
- Transcriptional profile of GTP-mediated differentiation of C2C12 skeletal muscle cells.Purinergic signalling · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activation of receptor for advanced glycation end products (RAGE) by its ligand, HMGB1, stimulates myogenesis via a Cdc42-Rac1-MKK6-p38 mitogen-activated protein kinase pathway. In addition, functional inactivation of RAGE in myoblasts results in reduced myogenesis, increased proliferation, and tumor formation in vivo. We show here that TE671 rhabdomyosarcoma cells, which do not express RAGE, can be induced to differentiate on transfection with RAGE (TE671/RAGE cells) but not a signaling-deficient RAGE mutant (RAGEDeltacyto) (TE671/RAGEDeltacyto cells) via activation of a Cdc42-Rac1-MKK6-p38 pathway and that TE671/RAGE cell differentiation depends on RAGE engagement by HMGB1. TE671/RAGE cells also show p38-dependent inactivation of extracellular signal-regulated kinases 1 and 2 and c-Jun NH(2) terminal protein kinase and reduced proliferation, migration, and invasiveness and increased apoptosis, volume, and adhesiveness in vitro; they also grow smaller tumors and show a lower tumor incidence in vivo compared with wild-type cells. Two other rhabdomyosarcoma cell lines that express RAGE, CCA and RMZ-RC2, show an inverse relationship between the level of RAGE expression and invasiveness in vitro and exhibit reduced myogenic potential and enhanced invasive properties in vitro when transfected with RAGEDeltacyto. The rhabdomyosarcoma cell lines used here and C2C12 myoblasts express and release HMGB1, which activates RAGE in an autocrine manner. These data suggest that deregulation of RAGE expression in myoblasts might concur in rhabdomyosarcomagenesis and that increasing RAGE expression in rhabdomyosarcoma cells might reduce their tumor potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.